U.S. Markets closed
  • S&P 500

    4,141.59
    +13.60 (+0.33%)
     
  • Dow 30

    33,677.27
    -68.13 (-0.20%)
     
  • Nasdaq

    13,996.10
    +146.10 (+1.05%)
     
  • Russell 2000

    2,228.92
    -4.86 (-0.22%)
     
  • Crude Oil

    60.45
    +0.75 (+1.26%)
     
  • Gold

    1,746.20
    +13.50 (+0.78%)
     
  • Silver

    25.41
    +0.54 (+2.16%)
     
  • EUR/USD

    1.1950
    +0.0033 (+0.2749%)
     
  • 10-Yr Bond

    1.6230
    -0.0520 (-3.10%)
     
  • Vix

    16.65
    -0.26 (-1.54%)
     
  • GBP/USD

    1.3753
    +0.0011 (+0.0784%)
     
  • USD/JPY

    109.0510
    -0.3250 (-0.2971%)
     
  • BTC-USD

    63,076.17
    +2,947.85 (+4.90%)
     
  • CMC Crypto 200

    1,352.18
    +58.19 (+4.50%)
     
  • FTSE 100

    6,890.49
    +1.37 (+0.02%)
     
  • Nikkei 225

    29,751.61
    +212.91 (+0.72%)
     

Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
Aclaris Therapeutics, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

WAYNE, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 8:00 a.m. ET. Management will be available February 25th throughout the day for virtual one-on-one meetings.

A live audio webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

Aclaris Contact

investors@aclaristx.com